Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Satiogen Pharmaceuticals
AddedFeb 18, 2024
UpdatedJun 18, 2026
Satiogen Pharmaceuticals

Satiogen Pharmaceuticals

Series A

Satiogen Pharmaceuticals: Innovating diabetes and obesity treatments with novel-target therapies.

HQ
San Diego, CA, US
Founded
2007
Overview
Compare
Fundraising
Employees

Satiogen Pharmaceuticals is a specialty pharma company based in San Diego, California, focused on developing novel-target therapies for treating type 2 diabetes and obesity. Their products include a substitute for metformin in gliptin formulations and an OTC nutraceutical designed to reduce body weight and postprandial glucose, aiming to help doctors manage these conditions without invasive interventions.

Satiogen Pharmaceuticals has made significant strides in the field of metabolic mechanism therapy, offering innovative solutions that regulate nutrient intake and glucose levels. Their impact is notable in providing alternatives to traditional diabetes treatments, potentially improving patient outcomes and quality of life.

Satiogen Pharmaceuticals - Similar Companies

Satiety logo

Satiety

Glyscend logo

Glyscend

glyscend.com

Energesis Pharmaceuticals logo

Energesis Pharmaceuticals

Endogenex logo

Endogenex

endogenex.com

Sensulin logo

Sensulin

sensulin.com

Restor Metabolix logo

Restor Metabolix

Elcelyx Therapeutics logo

Elcelyx Therapeutics

Metabolic Solutions Development logo

Metabolic Solutions Development

msdrx.com

KinDex Pharmaceuticals logo

KinDex Pharmaceuticals

Zenomics logo

Zenomics

Equator Therapeutics logo

Equator Therapeutics

Gila Therapeutics logo

Gila Therapeutics

Evoke Pharma logo

Evoke Pharma

evokepharma.com

Sapir Pharmaceuticals logo

Sapir Pharmaceuticals

Spinogenix logo

Spinogenix

spinogenix.com

Satiogen Pharmaceuticals - Quick Facts

Who are Satiogen Pharmaceuticals' competitors?

Companies similar to Satiogen Pharmaceuticals include Satiety, Glyscend, Energesis Pharmaceuticals and Endogenex.

When was Satiogen Pharmaceuticals founded?

Satiogen Pharmaceuticals was founded in 2007.

Where is Satiogen Pharmaceuticals' headquarters located?

Satiogen Pharmaceuticals' headquarters is located in San Diego, CA, US.

When was Satiogen Pharmaceuticals' last funding round?

Satiogen Pharmaceuticals' most recent funding round was for $700k (USD) in April 2008.

How much has Satiogen Pharmaceuticals raised to-date?

As of Apr 15, 2008, Satiogen Pharmaceuticals has raised a total of $700k (USD).

How many employees does Satiogen Pharmaceuticals have?

Satiogen Pharmaceuticals has 5 employees as of Feb 4, 2024.

Satiogen Pharmaceuticals - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Diabetes Treatment
  • Pharmaceuticals
Tags
  • Healthcare
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified